Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Rigel Pharmaceuticals, Inc.”

373 pharma patents match "Rigel Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 373
Index total 30,257
Page 9 / 16

Quick answer

This filtered view shows 373 pharmaceutical patents matching "Rigel Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

373 results for “Rigel Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 8796259

    N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as axl inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted
  2. US 8791136

    Substituted pyridine, pyridazine, pyrazine and pyrimidine compounds and methods for using the same

    Rigel Pharmaceuticals, Inc. · Granted Jul 29, 2014 · Expires Jul 24, 2034

    granted
  3. US 8785449

    Carboxamide compounds and methods for using the same

    Rigel Pharmaceuticals, Inc. · Granted Jul 22, 2014 · Expires Jul 17, 2034

    granted
  4. US 8785437

    Prodrugs of 2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Jul 22, 2014 · Expires Jul 17, 2034

    granted
  5. US 8771648

    (Trimethoxyphenylamino) pyrimidinyl formulations

    Rigel Pharmaceuticals, Inc. · Granted Jul 8, 2014 · Expires Jul 3, 2034

    granted
  6. US 8748597

    2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Jun 10, 2014 · Expires Jun 5, 2034

    granted
  7. US 8741898

    Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Jun 3, 2014 · Expires May 29, 2034

    granted
  8. US 8735418

    Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases

    Rigel Pharmaceuticals, Inc. · Granted May 27, 2014 · Expires May 22, 2034

    granted
  9. US 8735400

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted May 27, 2014 · Expires May 22, 2034

    granted
  10. US 8729087

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted May 20, 2014 · Expires May 15, 2034

    granted
  11. US 8710223

    Protein kinase C inhibitors and uses thereof

    Rigel Pharmaceuticals, Inc. · Granted Apr 29, 2014 · Expires Apr 24, 2034

    granted
  12. US 8697727

    N-substituted-heterocycloalkyloxybenzamide compounds and methods of use

    Rigel Pharmaceuticals, Inc. · Granted Apr 15, 2014 · Expires Apr 10, 2034

    granted
  13. US 8658669

    Bridged bicyclic heteroaryl substituted triazoles useful as Axl inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Feb 25, 2014 · Expires Feb 20, 2034

    granted
  14. US 8652492

    Wet granulation using a water sequestering agent

    Rigel Pharmaceuticals, Inc. · Granted Feb 18, 2014 · Expires Feb 13, 2034

    granted
  15. US 8642593

    2,4-pyrimidinediamine compounds and prodrugs and their uses

    Rigel Pharmaceuticals, Inc. · Granted Feb 4, 2014 · Expires Jan 30, 2034

    granted
  16. US 8637038

    Methods for inhibiting allograft rejection

    Rigel Pharmaceuticals, Inc. · Granted Jan 28, 2014 · Expires Jan 23, 2034

    granted
  17. US 8618331

    Polycyclic heteroaryl substituted triazoles useful as axl inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Dec 31, 2013 · Expires Dec 26, 2033

    granted
  18. US 8618095

    2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses

    Rigel Pharmaceuticals, Inc. · Granted Dec 31, 2013 · Expires Dec 26, 2033

    granted
  19. US 8609650

    Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as Axl inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Dec 17, 2013 · Expires Dec 12, 2033

    granted
  20. US 8575165

    Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds

    Rigel Pharmaceuticals, Inc. · Granted Nov 5, 2013 · Expires Oct 31, 2033

    granted
  21. US 8569340

    AMPK-activating piperidinyloxypyiridine carboxamide and sulfonamide compounds and methods for using the same

    Rigel Pharmaceuticals, Inc. · Granted Oct 29, 2013 · Expires Oct 24, 2033

    granted
  22. US 8563569

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Oct 22, 2013 · Expires Oct 17, 2033

    granted
  23. US 8563559

    Pinane-substituted pyrimidinediamine derivatives useful as Axl inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Oct 22, 2013 · Expires Oct 17, 2033

    granted
  24. US 8563716

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Oct 22, 2013 · Expires Oct 17, 2033

    granted